Frankie Chor-Cheung Tam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frankie Chor-Cheung Tam has a total of 378 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Ka Wong
Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong; Cardiology Division, Department of Medicine, Queen Mary Hospital, Hong Kong
9 shared publications - Alessandra Scoccia
Division of Cardiology, Ospedale "Sant'Anna", Ferrara, Italy
5 shared publications - Cesar Rodrigo Zoni
Instituto de Cardiología de Corrientes “Juana F. Cabral”, Corrientes, Argentina
5 shared publications - Dinaldo Cavalcanti de Oliveira
Pronto de Socorro Cardiologico Prof. Luis Tavares, Centro PROCAPE, Federal University of Pernambuco, Recife 50670-901, Brazil
5 shared publications - Enrico Fabris
Cardiothoracovascular Department, University of Trieste, Trieste, Italy
5 shared publications - Gianluca Caiazzo
Division of Cardiology, Ospedale “G Moscati”, 81031 Aversa, Italy
5 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11)
Chest Pain Center Accreditation and Outcomes in Patients With Acute Chest Pain
- 23 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11)
Open AccessChest Pain Center Accreditation and Outcomes in Patients With Acute Chest Pain
- Open Access
- 1 July 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (8) , 1340-1352
Wearable Electrocardiogram Technologies for the Early Detection of Acute Coronary Syndromes
- 1 July 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (8) , 1340-1352
Open AccessWearable Electrocardiogram Technologies for the Early Detection of Acute Coronary Syndromes
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1707-1709
Chordal-Zone Free Externalization of Retrograde Wire to Facilitate Base-to-Tip LAMPOON
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1707-1709
Chordal-Zone Free Externalization of Retrograde Wire to Facilitate Base-to-Tip LAMPOON
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1607-1619
BenchTop Validation of UNICORN Leaflet Modification Technique in Redo–Transcatheter Aortic Valve Replacement
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1607-1619
BenchTop Validation of UNICORN Leaflet Modification Technique in Redo–Transcatheter Aortic Valve Replacement
- Open Access
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3560
Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry
Background. Despite technological innovations and improvements in stents and devices, sex-related discrepancies are still reported in the outcomes after ST-segment elevation myocardial infarction (STEMI), depending on biological and sex-specific pathophysiological differences, which have not been completely understood. The aim of the present study was to provide real-world data on the prognostic role of sex among patients with STEMI, enclosed into a recent up-to-date international registry. Methods. The ISACS-STEMI COVID-19 is a large-scale retrospective registry, including STEMI patients treated with mechanical reperfusion between 1 March and 30 June, 2019 and 2020. Patients, treated in 109 centers across Europe, Latin America, Southeast Asia, and North Africa, were grouped according to sex. Primary endpoint: In-hospital mortality; secondary endpoints: Time delay, 30-day mortality, and postprocedural Thrombolysis In Myocardial Infarction (TIMI) 3 flow. Results. We included 16,083 patients, 24.3% females (54.3% hospitalized in 2019, 45.7% in 2020). Women with STEMI were older, more often diabetic and hypertensive (p < 0.001), with a higher prevalence of hypercholesterolemia (p = 0.02), longer ischemia time (p = 0.01), ambulance referral (p = 0.03) and cardiogenic shock at presentation (p = 0.05), but less frequently smokers, with a previous cardiovascular event (p < 0.001) or anterior STEMI (p = 0.03) as compared to males. Preprocedural TIMI 0 flow, multivessel disease, need for thrombectomy (p < 0.001 and p = 0.001, respectively), use of Glycoprotein IIbIIIa inhibitors or cangrelor, radial access and implantation of drug-eluting stents (p < 0.001, p < 0.001 and p = 0.001, respectively) were also more common in men. Impaired postprocedural epicardial reperfusion (TIMI flow 0–2) was observed more frequently in females as compared to males (10% vs. 7.2%; adjusted OR [95% CI] = 1.30 [1.13–1.49], p = 0.01). In-hospital mortality was 5.8%, significantly higher among women (8.3% vs. 5%, p < 0.001, adjusted HR [95% CI] = 1.26 [1.06–1.5], p = 0.01). Similar data were observed for 30-day mortality (10.3% vs. 6.2%, p < 0.001, adjusted HR [95% CI] = 1.22 [1.06–1.38], p = 0.007). Conclusions. Among STEMI patients being treated with the most updated standard of care for primary percutaneous coronary intervention, female sex is still associated with higher complexity and impaired prognosis, displaying suboptimal epicardial reperfusion and increased in-hospital and 30-day mortality.
- 7 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3560
Open AccessPersisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry
Background. Despite technological innovations and improvements in stents and devices, sex-related discrepancies are still reported in the outcomes after ST-segment elevation myocardial infarction (STEMI), depending on biological and sex-specific pathophysiological differences, which have not been completely understood. The aim of the present study was to provide real-world data on the prognostic role of sex among patients with STEMI, enclosed into a recent up-to-date international registry. Methods. The ISACS-STEMI COVID-19 is a large-scale retrospective registry, including STEMI patients treated with mechanical reperfusion between 1 March and 30 June, 2019 and 2020. Patients, treated in 109 centers across Europe, Latin America, Southeast Asia, and North Africa, were grouped according to sex. Primary endpoint: In-hospital mortality; secondary endpoints: Time delay, 30-day mortality, and postprocedural Thrombolysis In Myocardial Infarction (TIMI) 3 flow. Results. We included 16,083 patients, 24.3% females (54.3% hospitalized in 2019, 45.7% in 2020). Women with STEMI were older, more often diabetic and hypertensive (p < 0.001), with a higher prevalence of hypercholesterolemia (p = 0.02), longer ischemia time (p = 0.01), ambulance referral (p = 0.03) and cardiogenic shock at presentation (p = 0.05), but less frequently smokers, with a previous cardiovascular event (p < 0.001) or anterior STEMI (p = 0.03) as compared to males. Preprocedural TIMI 0 flow, multivessel disease, need for thrombectomy (p < 0.001 and p = 0.001, respectively), use of Glycoprotein IIbIIIa inhibitors or cangrelor, radial access and implantation of drug-eluting stents (p < 0.001, p < 0.001 and p = 0.001, respectively) were also more common in men. Impaired postprocedural epicardial reperfusion (TIMI flow 0–2) was observed more frequently in females as compared to males (10% vs. 7.2%; adjusted OR [95% CI] = 1.30 [1.13–1.49], p = 0.01). In-hospital mortality was 5.8%, significantly higher among women (8.3% vs. 5%, p < 0.001, adjusted HR [95% CI] = 1.26 [1.06–1.5], p = 0.01). Similar data were observed for 30-day mortality (10.3% vs. 6.2%, p < 0.001, adjusted HR [95% CI] = 1.22 [1.06–1.38], p = 0.007). Conclusions. Among STEMI patients being treated with the most updated standard of care for primary percutaneous coronary intervention, female sex is still associated with higher complexity and impaired prognosis, displaying suboptimal epicardial reperfusion and increased in-hospital and 30-day mortality.
- Open Access
- 18 April 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (6) , 989-992
The Hong Kong Registry for Percutaneous Ventricular Assist Device
- 18 April 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (6) , 989-992
Open AccessThe Hong Kong Registry for Percutaneous Ventricular Assist Device
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (2) , e039113
Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation
Background: Concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants (DOACs) for COVID‐19 is challenging due to potential drug–drug interactions. This study assessed the safety and effectiveness of nirmatrelvir/ritonavir compared with RNA‐dependent RNA polymerase inhibitors in patients with COVID‐19 and atrial fibrillation treated with a DOAC. Methods: We conducted a territory‐wide retrospective study of patients with COVID‐19 hospitalized in Hong Kong between January and November 2022 for antiviral therapy who had atrial fibrillation managed with a DOAC. Clinical outcomes including 30‐day all‐cause death, ischemic stroke, myocardial infarction, and bleeding events were evaluated. Results: Overall, 1297 (91%) patients were prescribed an RNA‐dependent RNA polymerase inhibitor, and 127 (9%), nirmatrelvir/ritonavir. Among patients treated with nirmatrelvir/ritonavir, 77 (60.6%) continued DOAC treatment, 30 (23.6%) switched to low‐molecular‐weight heparin, and 20 (15.7%) withheld anticoagulation therapy. After propensity score matching (n=1270), 1143 and 127 patients were in the RNA‐dependent RNA polymerase inhibitor and nirmatrelvir/ritonavir groups, respectively. On univariate analysis, the 30‐day all‐cause death was lower in the nirmatrelvir/ritonavir group (5.51% versus 12.1%; P =0.033). However, after adjusting for covariates including age and COVID‐19 severity, this difference was no longer statistically significant. The incidence of bleeding events was not significantly different between groups ( P =0.654), and there were no statistically significant differences in ischemic stroke, myocardial infarction, or need for ventilatory support. Conclusions: In a territory‐wide cohort of hospitalized patients with COVID‐19 and atrial fibrillation on a DOAC, nirmatrelvir/ritonavir therapy was associated with lower unadjusted 30‐day all‐cause death compared with RNA‐dependent RNA polymerase inhibitors; however, this difference was not significant after adjusting for age and COVID‐19 severity.
- 20 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (2) , e039113
Open AccessSafety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation
Background: Concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants (DOACs) for COVID‐19 is challenging due to potential drug–drug interactions. This study assessed the safety and effectiveness of nirmatrelvir/ritonavir compared with RNA‐dependent RNA polymerase inhibitors in patients with COVID‐19 and atrial fibrillation treated with a DOAC. Methods: We conducted a territory‐wide retrospective study of patients with COVID‐19 hospitalized in Hong Kong between January and November 2022 for antiviral therapy who had atrial fibrillation managed with a DOAC. Clinical outcomes including 30‐day all‐cause death, ischemic stroke, myocardial infarction, and bleeding events were evaluated. Results: Overall, 1297 (91%) patients were prescribed an RNA‐dependent RNA polymerase inhibitor, and 127 (9%), nirmatrelvir/ritonavir. Among patients treated with nirmatrelvir/ritonavir, 77 (60.6%) continued DOAC treatment, 30 (23.6%) switched to low‐molecular‐weight heparin, and 20 (15.7%) withheld anticoagulation therapy. After propensity score matching (n=1270), 1143 and 127 patients were in the RNA‐dependent RNA polymerase inhibitor and nirmatrelvir/ritonavir groups, respectively. On univariate analysis, the 30‐day all‐cause death was lower in the nirmatrelvir/ritonavir group (5.51% versus 12.1%; P =0.033). However, after adjusting for covariates including age and COVID‐19 severity, this difference was no longer statistically significant. The incidence of bleeding events was not significantly different between groups ( P =0.654), and there were no statistically significant differences in ischemic stroke, myocardial infarction, or need for ventilatory support. Conclusions: In a territory‐wide cohort of hospitalized patients with COVID‐19 and atrial fibrillation on a DOAC, nirmatrelvir/ritonavir therapy was associated with lower unadjusted 30‐day all‐cause death compared with RNA‐dependent RNA polymerase inhibitors; however, this difference was not significant after adjusting for age and COVID‐19 severity.
- Open Access
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 94-97
Early Clinical and Echocardiographic Outcomes of Tricuspid Transcatheter Edge-to-Edge Repair in Asian Patients
- 6 January 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (1) , 94-97
Open AccessEarly Clinical and Echocardiographic Outcomes of Tricuspid Transcatheter Edge-to-Edge Repair in Asian Patients
- Open Access
- 1 November 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (41) , 105918
Group G Streptococcus Infective Endocarditis Complicated by a Very Delayed Coronary Embolism
- 1 November 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (41) , 105918
Open AccessGroup G Streptococcus Infective Endocarditis Complicated by a Very Delayed Coronary Embolism
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Recreating the Crime Scene: Three-Dimensional Model to Analyze the Mechanism of Orbital Atherectomy Related Coronary Perforation
A 77-year-old woman with hypertension and diabetes presented with exertional angina and dyspnea. Subsequent workup showed severe aortic stenosis and severe calcified stenosis at the proximal left anterior descending artery. Clinical Images from Journal of Invasive Cardiology. calcified coronary artery coronary perforation Orbital atherectomy severe aortic stenosis
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Recreating the Crime Scene: Three-Dimensional Model to Analyze the Mechanism of Orbital Atherectomy Related Coronary Perforation
A 77-year-old woman with hypertension and diabetes presented with exertional angina and dyspnea. Subsequent workup showed severe aortic stenosis and severe calcified stenosis at the proximal left anterior descending artery. Clinical Images from Journal of Invasive Cardiology. calcified coronary artery coronary perforation Orbital atherectomy severe aortic stenosis